Blog

Amol Akhade: The choice of chemotherapy regimen for metastatic pancreatic cancer patients

Amol Akhade/hiranandanihospital.org

Nov 9, 2024, 12:35

Amol Akhade: The choice of chemotherapy regimen for metastatic pancreatic cancer patients

Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on LinkedIn:

“The survey results on the choice of chemotherapy regimen for metastatic pancreatic cancer patients who are medically fit have been revealed. With 412 votes collected, the outcomes align with expectations:

1. 75% of oncologists prefer Folfirinox for fit patients.
2. Nalirifox garners only 4% preference.
3. The remaining respondents opt for gemcitabine plus nab-paclitaxel, with some choosing modified Folfirinox.

All three options carry category 1 recommendations from NCCN.

While Folfirinox and Nalirifox show a similar median Overall Survival (OS) of 11.1 months based on cross-trial comparisons, Nalirifox’s lower preference may stem from higher cost concerns and similar survival benefits compared to the established Folfirinox. Folfirinox, although effective, presents higher toxicity levels and necessitates chemo port or PICC insertion.

Personally, I lean towards using modified Folfirinox to address toxicity concerns, supported by meta-analyses indicating maintained efficacy. Alternatively, for patients unfit for Folfirinox, gemcitabine plus nab-paclitaxel is a viable option.

Despite advancements in treatment regimens, the median OS remains at 11.1 months, emphasizing the ongoing need to enhance patient outcomes in pancreatic cancer care.”

Amol Akhade: The choice of chemotherapy regimen for metastatic pancreatic cancer patients

Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.